截至 2025 年 6 月 30 日，公司对募集资金项目累计投入 476,090,539.82 元， 证券代码：688351 证券简称：微电生理 公告编号：2025-016 上海微创电生理医疗科技股份有限公司 情况的专项报告 募集资金余额为人民币 643,049,108.16 元。2025 年 8 月 26 日，公司召开了第三 届董事会第十六次会议、第三届监事会第十六次会议，审议通过了《关于<2025 年半年度募集资金存放与实际使用情况的专项报告>的议案》。 | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | | | | | --- | --- | --- | --- | --- | --- | | 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | | | | | | | 一、募集资金基本情况 | | | | | | | 根据中国证券监督管理委员会出具的《关于同意上海微创电生理医疗科技 | | | | | | | 股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1587 号），公 | | | | | | | 司向社会公开发行人民币普通股（A ...

Core Viewpoint - The report provides a reasonable assurance conclusion regarding the use and storage of funds raised by Shanghai MicroPort EP Medical Technology Co., Ltd. for the year 2024, confirming compliance with relevant regulations and accurate reflection of the financial situation [2][4][5]. Fundraising Overview - The company raised a total of RMB 1,069,879,920.88 through the issuance of 70.6 million shares at a price of RMB 16.51 per share, with the funds verified by DaHua Accounting Firm [4][6]. - As of December 31, 2024, the total amount used from the raised funds was RMB 109,297,928.23, leaving a balance of RMB 687,376,885.41, which includes RMB 662,000,000.00 in bank wealth management products [4][8]. Fund Management - The company has established a management system for the raised funds, ensuring they are stored in dedicated accounts and used strictly for designated projects, with regular audits conducted by the sponsor [5][6]. - The company signed tripartite and quadripartite agreements with banks to ensure proper oversight of the funds, which have been effectively implemented [5][6]. Fund Usage - The funds were allocated to various projects, including RMB 44,175,632.76 for the electrophysiological intervention medical device R&D project, RMB 1,407,722.00 for production base construction, and RMB 63,714,573.47 for marketing service system construction [4][8]. - The company has not used idle funds for temporary working capital or other non-designated projects during the year [6][12]. Project Adjustments - The company has made adjustments to its investment projects, including extending the timeline for the electrophysiological intervention medical device R&D project to December 2027 due to the addition of new sub-projects [14][17]. - The production base construction project has been optimized to reduce costs, with the total investment adjusted from RMB 29,949.49 million to RMB 7,578.92 million [15][17]. - The marketing service system project has seen an increase in investment from RMB 14,376.84 million to RMB 17,522.51 million to enhance market penetration and service capabilities [18][19].